Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone

British Journal of Cancer

Volumn 111, Issue 12, 2014, Pages 2248-2253

  Lorente, D ^a   Omlin, A ^a,b   Ferraldeschi, R ^a   Pezaro, C ^a   Perez, R ^a   Mateo, J ^a   Altavilla, A ^a   Zafeirou, Z ^a   Tunariu, N ^a   Parker, C ^c   Dearnaley, D ^c   Gillessen, S ^b   De Bono, J ^a   Attard, G ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

abiraterone; androgen receptor; castration resistant prostate cancer; dexamethasone; glucocorticoid receptor; hormone therapy; prednisolone; steroid switch

Indexed keywords

ABIRATERONE; AMINOTRANSFERASE; BICALUTAMIDE; CABAZITAXEL; DEXAMETHASONE; DOCETAXEL; LACTATE DEHYDROGENASE; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT;

AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DISEASE COURSE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; HYPERALDOSTERONISM; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER INJURY; MALE; ORTHOSTATIC HYPOTENSION; PATIENT SAFETY; PRIORITY JOURNAL; SIDE EFFECT; TUMOR REGRESSION; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84927578069     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.531     Document Type: Article

References (12)

1. Arora V, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zhend D, Sawyers CL (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6): 1309-1322.
2. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27(23): 3742-3748.
3. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008) Phase i clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(28): 4563-4571.
4. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Foglman I, Langsteger W (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35(10): 1766-1774.
5. Costelloe CM, Chuang HH, Madewell JE, Ueno NT (2010) Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1: 80-92.
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 364(21): 1995-2005.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247.
8. Lan NC, Graham B, Bartter FC, Baxter JD (1982) Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids. J Clin Endocrinol Met 54(2): 332-342.
9. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28(9): 1481-1488.
10. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 367(13): 1187-1197.
11. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7): 1148-1159.
12. Venkitaraman Ramachandran, Thomas Karen, Murthy Vedang, Woode-Amissah Ruth, Dearnaley David Paul, Horwich Alan, Huddart Robert Anthony, De Bono Johann Sebastian, Parker Chris (2013) A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC. ASCO Meeting Abstracts 31(6-suppl): 123.